Researchers at the Dana-Farber Cancer Institute have developed a technology for screening thousands of drugs in freshly isolated human cancer cells, to help identify which drugs are most likely to be effective against those cancers.
The new approach, known as high-throughput dynamic BH3 profiling (HT-DBP), is a scaled-up version of a method created by Dana-Farber researchers that gauges how close tumor cells are to apoptosis after treatment with cancer drugs.
